Antivirals Market exceeded USD 47.7 Bn in 2021, due to the growing incidence rate of several infectious diseases including COVID-19 | insightSLICE
The global Antivirals market size was estimated to be US$ 47.7 billion in 2021 and is expected grow at a CAGR of 3.6% between 2023 to 2032.
Enormous growth opportunities are expected in the global antivirals market as many pharmaceutical companies have invested and continue to do so in the coming years. Several key players are actively involved in the research and development of antiviral drugs against novel diseases which will improve overall knowledge and understanding of these drugs.
The Covid-19 pandemic which affected millions of people across the world also ensured a rapid surge in the prescription of antiviral drugs to curb the disease and death burden in various countries. Not just companies but governments and national organizations are also getting actively developing new antiviral drugs post Covid-19 pandemic.
Access the sample report: https://www.insightslice.com/request-sample/1307
Global Antivirals Market Key Segments:
By Drug Class
- DNA polymerase inhibitors
- Reverse transcriptase inhibitors
- Protease inhibitors
- Neuraminidase inhibitors
- Others
By Type
- Branded
- Generic
By Age Group
- Adult
- Paediatric
- Geriatric
By Indication
- Influenza
- HIV AIDS
- Hepatitis
- Herpes simplex virus (HSV)
- Coronavirus infection
- Others
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Geography
- North America
- United States
- Canada
- Rest of North America
- Europe
- Germany
- United Kingdom
- Italy
- France
- Spain
- Rest of Europe
- Asia Pacific
- Japan
- India
- China
- Australia
- Rest of Asia Pacific
- Middle East & Africa
- UAE
- Saudi Arabia
- South Africa
- Rest of the Middle East & Africa
- South America
- Brazil
- Rest of South America
Viral diseases like HIV, Zika, Hepatitis, and Influenza have seen a rise in recent years and have therefore mobilized the pharmaceutical industry to develop new medications against these viruses. The requirement of continuous drug development owing to the ability to evolve viral genomes can make research and development challenges.
Patent rights and royalty fees that are granted for novel compounds against viral infections are very lucrative for big corporations. In most developed countries the antiviral drug market mostly consists of branded and licensed drugs. Established supply chains, increased public awareness, reduced legal hurdles and increased revenue opportunities are inducing big pharmaceutical companies to enter this sector.
The key players of the Global Antivirals Market are:
Key industry players in the antivirals market include AbbVie, Inc., Aurobindo Pharma Limited., Bristol-Myers Squibb, Cipla, Inc., GlaxoSmithKline PLC., Gilead Sciences, Johnson & Johnson, Sun Pharmaceutical Industries Ltd., etc.
Read more about the report inclusions: https://www.insightslice.com/antivirals-market
Major classes of Antivirals
The major classes of antivirals include reverse transcriptase inhibitors, DNA polymerase inhibitors, protease inhibitors, and neuraminidase inhibitors. The reverse transcriptase inhibitors generate the most revenue as of 2021. They are followed by classes like protease and DNA polymerase inhibitors which are currently being used for similar treatments with varying impacts. Combination therapies of different classes of antivirals are also being utilized for HIV treatment.
Reverse transcriptase inhibitors are also commonly utilized in resource-limited areas because of higher bioavailability, success rate, and affordability. A significant generic antiviral drug production market which can drive small-scale pharmaceutical production is also growing up. Other anti-retroviral drug classes will require substantial clinical research before their large-scale adoption and market growth.
Driving factors for Antivirals Market
Before the Covid-19 pandemic, HIV AIDS treatment was leading the global antiviral drugs market. Due to a large number of patients, the inability of immunological approaches and ineffective alternate therapies resulted in antiviral treatment growth against HIV.
All these features along with the growing prevalence of HIV infections are still dominating the demand for antivirals against HIV. Upscaling of current production capabilities, along with the need for advanced treatment will enable faster overall growth of the antiviral drugs market in coming years. Furthermore, governmental awareness programs against HIV in specific and sexually transmitted diseases, in general, have ensured the acceptance and knowledge dispensation of antivirals within the common public.
Request for a customization: https://www.insightslice.com/request-customization/1307
Regional performance of Antivirals Market
The current dominance of antivirals is observed in North American regions, especially in the United States. With the largest share of pharmaceutical companies present within its borders, the country is leading the development of the antivirals market.
Introduction, approval, and effective medications against various diseases are being done in the United States by many companies. Acceptance of such treatments at the lowest level is ensuring the highest market penetration of antivirals in American markets.
The antivirals experience overwhelming acceptance in Asia Pacific market. The huge patient population for several viral diseases including HIV is the primary driving factor for their demand. National policies and regulatory relaxations will also sufficiently induce large-scale growth of the antiviral drugs market across countries like China, Japan, and India. Thus, increasing global demand for antiviral medicines along with better products will ensure the rise of this segment.
Related reports:
Global Pharmaceutical Isolator Market: https://www.insightslice.com/pharmaceutical-isolator-market
Global Optical Lens Edger Market: https://www.insightslice.com/optical-lens-edger-market
Opportunities for the participants of Antivirals Market
Covid-19 antiviral therapies single-handedly accounted for more than 17% of the market share in 2021. Additionally, major pharmaceutical companies got involved in new antiviral drug formulations and production against the pandemic which further induced growth in this sector.
Collaborations between big corporations were also observed to cater during peak demands (eg., Cipla and Gilead Sciences collaborated for the production of Remdesivir). Similar strategic and economical partnerships can enable this sector to overcome the financial burden and tackle capacity building in the coming years.
Viral infections ranging from influenza and respiratory infections to HIV and Polio are being targeted by antiviral medications. The invention of new formulations alongside vaccination is driving global antiviral sales. Antivirals with the highest number of indications are present for HIV, Herpes, Hepatitis, Covid, and Ebola.
Regional viral outbreaks like swine flu, zika, MERS, etc, have shown small yet significant spikes in demand for antiviral drugs across the globe. The coronavirus pandemic was one of the biggest drivers of antiviral demand throughout the world offering unprecedented growth for this sector in a short span.
Proceed to purchase: https://www.insightslice.com/buy-now/1307
insightSLICE is a market intelligence and strategy consulting company. The company provides tailor-made and off the shelf market research studies. The prime focus of the company is on strategy consulting to provide end-to-end solutions. For more details, please contact our research and consulting team at info@insightslice.com.
Contact us:
Alex R
+1 707 736 6633
Editor Details
-
Company:
- insightSLICE
- Website:
